B
Bull
Bull · 25%CERO
$10.66
シナリオ価格
$0.095
-0.090 (-94.69%)終値時点
Loading chart…
- High
- 0.404
- Open
- 0.338
- VWAP
- 0.19
- Vol
- 114.68M
- Mkt Cap
- —
- Low
- 0.085
- Amount
- 22.33M
- EV/EBITDA, TTM
- 0.00
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
バリュエーション指標
The current forward P/E ratio for CERo Therapeutics Holdings Inc (CERO) is -0.02, compared to its 5-year average forward P/E of -0.04.
Alphio AI Price Scenarios for CERO
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding CERO
イベントタイムライン
ニュース
8.508-31NewsfilterSRX Global Acquires CERo Debt to Support R&D
9.006-15NewsfilterCER-1236 Clinical Trial Update
- 9.003-30Newsfilter
CERo Therapeutics Advances CER-1236 Clinical Trial in Hematologic Malignancies
- 9.002-04Newsfilter
CERo Therapeutics Presents CER-1236 Clinical Data at ASTCT Meeting
9.001-07GlobenewswireCERo Therapeutics Expands Clinical Trial Focus, Reports 61-Day Transfusion-Free Interval
CERO FAQ — answered by Alphio AI
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。